Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience

By Sue Sutter / Email the Author / Pharmaceutical Approvals Monthly January 2012, Vol. 17, No. 1
Drug Review Profile / Word Count: 1725 / Article # 06111201038

Executive Summary

FDA’s review of AstraZeneca’s platelet inhibitor ticagrelor was tinged by the agency’s earlier evaluation and delayed approval of Lilly/Daiichi’s prasugrel for acute coronary syndromes.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1725-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 5

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article